TandemAI

TandemAI is a pioneering drug discovery CRO that has built an integrated platform, TandemViz, to bridge the gap between advanced computational methods and experimental biology. The company leverages a combination of AI, physics-based simulations, and high-throughput wet lab capabilities to accelerate client programs from hit finding to lead optimization. With over 350 experts, a global presence, and more than 100 established partnerships, TandemAI is positioned as a key enabler for biopharma companies seeking to modernize their R&D workflows. Its recent $22M Series A extension and strategic merger indicate strong growth and validation of its integrated approach.

Integrated cloud-based platform (TandemViz) combining proprietary AI and physics-based computational tools with in-house wet lab services (medicinal chemistry, biological assays, peptide platform) for end-to-end drug discovery.

Competes with pure-play AI drug discovery companies (e.g., Recursion, Exscientia), traditional CROs building computational arms (e.g., Charles River, Evotec), and software providers (e.g., Schrödinger). Its key differentiator is the deep vertical integration of proprietary computational tools with in-house wet lab operations under a unified platform.